Background. Both intrauterine and sexual transmission of human herpesvirus (HHV)-6 and HHV-7 have been suggested, and congenital HHV-6 infection does occur. We prospectively studied HHV-6 and HHV-7 at multiple sites in pregnant women to determine the characteristics of these viruses at repeated time points.
Human herpesvirus (HHV)-6 and HHV-7 are b-lymphotropic viruses that are closely related to human cytomegalovirus (CMV) and that cause universal infection during infancy or early childhood [1, 2] . Primary infection with HHV-6 causes an undifferentiated febrile illness, with a subset of children developing roseola infantum [3] . A small percentage of children with roseola have primary infection with HHV-7 [1, 4] .
After primary infection, HHV-6 remains latent or persistent in the peripheral blood mononuclear cells (PBMCs), central nervous system, salivary glands, and female genital tract [5, 6] . Although it is presumed that infants acquire primary infection with HHV-6 from the saliva of asymptomatic adults, congenital infection with HHV-6 has been well documented and occurs in 1% of newborns [7, 8] . The biological mechanisms responsible for this mode of transmission are unknown, and the clinical relevance is presently undefined but may be similar to that for CMV and be associated with developmental disability. In addition, recent evidence suggests that the genome of HHV-6 may be integrated into human chromosomes at a frequency of 0.2%-0.8% and may be of germ cell origin [9] [10] [11] [12] [13] .
Limited studies have been performed to understand more fully intrauterine and sexual transmission of HHV-6 and HHV-7. HHV-6 DNA has been detected in the vaginal secretions of women attending a sexually transmitted disease clinic and in cervical samples from pregnant women [14, 15] . Reactivation of HHV-6 during pregnancy has been suggested by an increased frequency of DNA detection in peripheral blood or vaginal swabs of pregnant women during early gestation relative to the third trimester or delivery [16, 17] .
Because HHV-6 and HHV-7 cause ubiquitous infection and remain latent, it is difficult to determine the relevance of detecting HHV-6 or HHV-7 DNA in blood or cervical samples without information on the replicative state of the virus. No study has examined blood, cervical, and placental samples longitudinally for HHV-6 and HHV-7 with a combination of methods capable of distinguishing between latent and actively replicating virus. Our aim was to prospectively study a large cohort of pregnant women for evidence of infection with HHV-6 and HHV-7 in the blood and genital tract and to study the prevalence and characteristics of HHV-6 and/ or HHV-7 at these sites at repeated points during pregnancy. In addition, we sought to determine whether reactivation of HHV-6 and/or HHV-7 occurs during pregnancy and whether reactivation is associated with placental infection with HHV-6 and/or HHV-7.
METHODS

Study Subjects
A sample of healthy immunocompetent pregnant women у18 years of age attending the routine obstetric clinic at the University of Rochester Medical Center (Rochester, New York) were invited to enroll in the present prospective study from 1 October 2000 to 31 October 2003. All eligible subjects were approached when the study nurse was available at the clinic, but study personnel were not present every day. Blood and cervical secretions were obtained at the first or second prenatal visit in conjunction with routine prenatal tests. During the second half of pregnancy, blood was obtained at the time of glucose tolerance testing, and cervical secretions were obtained in conjunction with group B streptococcal screening. If possible, a blood sample was also collected at the time of delivery or postpartum, as was cord blood and a sample of placenta. For women who presented early during pregnancy, we attempted to collect a sample during each trimester of pregnancy. Concurrent with this study was a longitudinal study of congenital infection with HHV-6, and some of the subjects from this study chose to enroll their newborns for further follow-up.
Control women were enrolled from the colposcopy clinic at the University of Rochester Medical Center. Subjects who provided both a blood sample and a cervical swab were included in the analyses, and each had only 1 visit.
We defined congenital infection with HHV-6 as the presence of HHV-6 DNA in a cord blood mononuclear cell sample. The Research Subjects Review Board of the University of Rochester approved the present study; all subjects provided informed consent, and a $20 honorarium was provided after each visit.
Laboratory Methods
Specimen processing. PBMCs were isolated via gradient centrifugation. Cell pellets were used for (1) DNA polymerase chain reaction (PCR), (2) real-time quantitative PCR (qPCR), and (3) reverse-transcriptase PCR (RT-PCR) analyses. Fullthickness placental samples were obtained from the site of attachment of the umbilical cord and placed in Tri Reagent BD (Molecular Research Center). The sample was ground in Tri Reagent, and the manufacturer's protocol was followed to isolate the RNA or DNA. The cervical swabs were placed in Tri Reagent LS on collection, and RNA or DNA isolation was performed.
Nested PCR for HHV-6 and HHV-7. The PCR protocol was as published elsewhere and was followed by oligohybridization with specific probes for HHV-6 variants A and B and for HHV-7 [7] . These assays reliably detect р10 genomic copies. Positive and negative controls were included along with bglobin primers as performance controls.
Nested RT-PCR for HHV-6 and HHV-7. An RT-PCR assay for HHV-6 was performed as described elsewhere and amplifies the gp82-105 mRNA of HHV-6 [5] . The probe sequence used was 5 -GCTCCCGAAAGCGCCATA-3 and has been modified from the published report on the basis of sequence information for HHV-6 variant B [18] . The RT-PCR for HHV-6 detects !10 mRNA copies.
The RT-PCR assay for HHV-7 was developed in our laboratory. Briefly, the external primer sequences were 5 -CATGCA-CAACGCAAGCTCTACTA-3 (G1) and 5 -ACGTAGTTTCGT-GCAGTTGTATCGT-3 (G2). The PCR profile was 48ЊC for 45 min; then 35 cycles of 64ЊC for 45 s, 72ЊC for 45 s, and 94ЊC for 1 min; then 64ЊC for 2 min; and finally 72ЊC for 8 min. The internal primer sequences were 5 -GCTTGTTAGAATACA-CAAGATGTACA-3 (G3) and 5 -CTGTCTAATAATGTCTAT-GTCTCTCCA-3 (G4); the probe was 5 -GCTATTCCGCTGTA-GCTACG-3 . The second-round PCR conditions were identical to those for the HHV-6 RT-PCR. This method detects 5 copies, or fg of RNA in a background of 0.21 mg
Ϫ3
2.15 ϫ 10 of negative cord blood RNA by gel electrophoresis, with specificity confirmed by hybridization.
While the present study was ongoing, we determined that there was no benefit to testing samples by RT-PCR that were negative for HHV-6 or HHV-7 DNA; therefore, partway through the study, we altered our protocol to include testing by RT-PCR only for samples that contained HHV-6 or HHV-7 DNA by qualitative PCR.
qPCR for HHV-6. Real-time qPCR for the U38 gene of HHV-6 was performed as described elsewhere [19] , with 1 modification. The forward primer used for these experiments was 5 -TGCTTCTGTAACGTGTCTTGGA-3 (sense) and contained 1 less adenine molecule on the 3 end than the published primer. Briefly, samples positive for HHV-6 DNA by qualitative PCR were purified using the Wizard SV Genomic DNA purification system (Promega) and were concentrated ∼10-fold, and the DNA concentration was measured spectrophometrically. Each sample was run in triplicate. The limit of detection of this assay is 10 copies. Mean values were used if results were available from 2 or more wells, and the results are reported as copies of HHV-6 per microgram of DNA. If 2 or more wells did not have measurable copy numbers, the result was set at 5 copies/mL, because the qPCR was performed only on samples that had a positive reaction in the qualitative PCR, which was able to detect !10 copies.
Statistical Analysis
Because of the nature of our sampling protocol, not all subjects had blood obtained during each trimester of pregnancy. Therefore, the primary analyses focused on the first sample (for each site) obtained during the first half of pregnancy and the last sample (for each site) obtained during the second half of pregnancy. Analyses were performed to compare the rates of detection of HHV-6 and HHV-7 DNA in pregnant women, to compare the rates of detection and characteristics of HHV-6 and HHV-7 infection during the first and second halves of pregnancy, to examine the associations between detection of HHV-6 and HHV-7 DNA in the blood and the cervices of pregnant women, and to compare the rates of detection and characteristics of HHV-6 and HHV-7 infection between pregnant women and control women. Logistic regression analyses were used for this purpose, and generalized estimating equations [20] were used to account for within-subject correlation where appropriate. As a secondary analysis, we evaluated a subset of subjects with paired blood samples and/or paired cervical swabs obtained at least 14 weeks apart during pregnancy to examine changes in HHV-6 and HHV-7 in individual subjects over time. McNemar's test was used to compare the rates of detection of HHV-6 and HHV-7 DNA between the first and second time points in these paired samples.
RESULTS
Subject characteristics.
We enrolled 104 pregnant women and 31 control women over 37 months ( (table 2) . This was also true for the second half of pregnancy, and overall these differences were highly significant (66.9% for HHV-7 and 22.2% for HHV-6;
). Despite the greater rate of HHV-P ! .0001 7 DNA detection in PBMC samples, cervical swabs contained HHV-6 DNA 7.5% of the time, but only 3.0% of samples had HHV-7 DNA. This difference was not significant ( ). P p . 19 The rate of detection of HHV-6 and HHV-7 DNA in blood and cervical samples from pregnant women did not change between the first and second halves of pregnancy (table 2) . Slightly more than half of all PBMC samples from pregnant women contained only HHV-7 DNA (89/176 [50.6%]), whereas 27.3% (48/176) were negative for both HHV-6 and HHV-7 DNA. Seventeen percent of pregnant women (30/176) had HHV-7 and HHV-6 DNA detected simultaneously in a PBMC sample. This was different from the results for the cervical swabs, among which 135 of 150 (90%) were negative for both HHV-6 and HHV-7 DNA. HHV-6 and HHV-7 DNA were not simultaneously detected in any cervical swabs.
Among control subjects, HHV-6 and HHV-7 DNA was detected in 19.4% and 80.6% of the PBMC samples and in 3.3% and 3.2% of the cervical swabs, respectively. One of these subjects had HHV-6 DNA only in a cervical swab, and another individual had HHV-7 DNA in both a blood sample and a cervical swab. HHV-6 DNA was detected in the cervical swabs of pregnant women (7.5%) more commonly than in the cervical swabs of control women (3.3%); however, this difference was not significant ( ). P p .44 A positive association between the detection of HHV-6 DNA in cervical secretions and PBMC samples was identified. A high percentage (72.3%) of pregnant women with HHV-6 DNA in cervical swabs also had HHV-6 DNA in PBMC samples, whereas only 18.5% of pregnant women with cervical swabs negative for HHV-6 DNA had HHV-6 DNA in their blood (odds ratio, 12.9 [95% confidence interval, 2.9-57.9]; P p ). This pattern was similar in the separate samples ob-.0009 tained during the first and second halves of pregnancy. No association between PBMC samples and cervical swabs was evident for HHV-7: pregnant women had a similar likelihood of having HHV-7 DNA in their PBMC samples regardless of whether the cervical swab was positive (60% with positive PBMC samples) or negative (65.7% with positive PBMC samples) for HHV-7 DNA ( ). P p .67 Samples from pregnant women with detectable HHV-6 DNA were segregated into 2 subgroups on the basis of the measured viral load (figure 1). High viral loads were associated with having HHV-6 DNA present in every sample (figure 2). In light of these data, we believe that PBMC samples from pregnant women containing у10,000 HHV-6 genomic copies/mg of DNA are indicative of chromosomal integration of HHV-6.
Evidence of HHV-6 and HHV-7 replication. We did not find evidence of actively replicating HHV-6 by RT-PCR in PBMC samples or cervical swabs from any pregnant women or control women. Active infection with HHV-7 was detected by RT-PCR in 1 PBMC sample (1.2%) from a pregnant woman during the first half of pregnancy. The same sample contained HHV-6 DNA but was negative by RT-PCR for active HHV-6 replication. A repeat blood sample and cervical swab were obtained 6 days later. Her blood sample contained only HHV-7 DNA, and the cervical swab had no detectable HHV-6 or HHV-7 DNA. A control subject had evidence of active replication of HHV-7 in a cervical swab (4%) by RT-PCR. Her blood sample was negative for HHV-6 DNA and RNA but did contain HHV-7 DNA.
HHV-6 variant types. The majority of both PBMC samples and cervical swabs that were positive for HHV-6 DNA contained variant B (table 2). The frequency of detection of HHV-6 variant A did not significantly change from the first to the second half of pregnancy for either PBMC samples (from 26% to 7%; ) or cervical swabs (from 40% to 17%; P p .16 P p ). . 40 Six pregnant women had HHV-6 DNA detected on 11 occasion or from 11 site. Three women had the same variant of HHV-6 DNA present in all blood samples and cervical swabs during the first and second halves of pregnancy. One had var- Analysis of paired data. Of the 104 pregnant women in the study, 83 had paired samples obtained from either the blood or the cervix (or both) that were separated in time by at least 14 weeks; these women were analyzed longitudinally (table 1). The rates of detection of HHV-6 DNA in PBMC samples during the first and second halves of pregnancy were similar to those for the entire cohort (27.7% and 23.1%, respectively), as was the detection of HHV-7 DNA (71.2% and 69.7%, respectively). The rate of detection of HHV-6 DNA in cervical swabs among this group was 9.3%; for HHV-7, it was 3.1%. Pregnant women with HHV-6 DNA detected in PBMC samples during the first half of pregnancy were not more likely than the rest of the group to have HHV-6 DNA present during the second half of pregnancy ( ); the same was true of HHV-7 detection P p .55 in PBMC samples ( ). Six women from this group had P p .83 HHV-6 DNA detected in their cervical swabs. The median viral load in the cervical swabs from the 3 women who had HHV-6 detected on only 1 occasion was 170 copies/mg of DNA. Two of these 3 subjects had paired PBMC samples that also contained HHV-6 DNA. The median viral load in cervical swabs from 3 women with HHV-6 DNA detected on 11 occasion was copies/mg of DNA, and all of their paired PBMC 5 1.1 ϫ 10 samples contained HHV-6 DNA. No pregnant woman had HHV-7 detected in a cervical swab on 11 occasion.
Transmission. Of the 33 placental samples that were sufficient for HHV-6 testing, 3 (9%) contained HHV-6 DNA. Of these 3 samples, 2 had a matched positive cord blood sample; the third sample (HHV-6 variant B) came from a pregnant woman who did not transmit HHV-6 to her infant but who had previous samples that were variously positive or negative for HHV-6 DNA, including a previous cervical sample with HHV-6 variant A. Of the remaining 30 placental samples that were negative for HHV-6 DNA, 9 had matching negative cord blood samples, and 21 did not have a cord blood sample available. One placental sample was positive for HHV-7 DNA only. There was no matched cord blood sample. No cord blood sample contained HHV-7 DNA.
We identified 5 infants with HHV-6 DNA present in cord blood samples (table 3) . For 2 mothers, all previous samples were positive (PBMC samples and cervical swabs) with high viral loads (median, HHV-6 genomic copies/mg of 5 1.6 ϫ 10 DNA). The third woman who transmitted HHV-6 did not have any blood sample or cervical swab positive before delivery but did have HHV-6 DNA detected in the placental sample, and this was the only sample with evidence of active HHV-6 replication by RT-PCR. Both the placental sample and blood from the infant after delivery had elevated viral loads. The fourth pregnant woman with evidence of congenital transmission had HHV-6 DNA detected in a PBMC sample during the first half of pregnancy with a low viral load (24 HHV-6 genomic copies/ ). n p 47 mg of DNA). This same sample was positive for HHV-7 DNA and was the only sample from a pregnant woman that contained evidence of active replication of HHV-7 by RT-PCR. No other sample was positive for HHV-6 DNA except for the infant's cord blood, which also contained a low copy number of HHV-6 DNA (81 genomic copies/mg of DNA). The fifth woman did not have any previous sample positive for HHV-6 DNA, and the cord blood sample contained only 39 genomic copies/mg of DNA.
DISCUSSION
The present prospective study allowed us to measure HHV-6 and HHV-7 DNA in blood as well as in cervical samples, and we found that the detection of HHV-7 in PBMCs is much more prevalent than the detection of HHV-6, in both pregnant and control women. Despite the lower rate of detection of HHV-6 DNA than HHV-7 DNA in blood samples, both are found at similarly low rates in the cervical swabs, as has been previously reported [17] . Our data strongly support an association between the presence of HHV-6 DNA in cervical samples and its presence in the PBMCs of pregnant women-an association that has not previously been recognized and that is not evident for HHV-7 DNA. Although the group of women with HHV-6 detected in cervical samples is small, our data suggest that this association may be due to 2 mechanisms, chromosomal integration with high copy numbers and repeated detection of DNA at all sites, as well as after infection, reactivation, or reinfection of the genital tract or peripheral blood.
The longitudinal design of the present study allowed us to evaluate the likelihood of repeated detection of HHV-6 or HHV-7 DNA at multiple sites during pregnancy. Only a minority of pregnant women had HHV-6 DNA identified in PBMC samples on repeated occasions. One interpretation of this finding is that reinfection or reactivation during pregnancy led to the first detection of HHV-6 DNA in PBMC samples during the second half of pregnancy in 17% of subjects (11/ 64 paired samples). Alternatively, given that the majority of women with intermittent detection of HHV-6 DNA had low viral loads, our methods may not have been sensitive enough to detect a low frequency of infected cells at every visit. Unfortunately, our sampling protocol did not allow for more frequent sample collection, and, therefore, we could not confirm reactivation by the RT-PCR assay for HHV-6 or HHV-7. Active replication of HHV-6 was demonstrated in 1 placental sample that was associated with congenital infection, despite a lack of previous detection of HHV-6 DNA during the pregnancy. This is the first documentation of active HHV-6 infection of the placenta associated with congenital infection. Congenital infection with HHV-6 was also found in the newborn of the only mother with evidence of active replication of HHV-7 in blood during pregnancy. HHV-7 induces reactivation of HHV-6 in vitro [21] . Our data suggest that active replication of HHV-7 may induce reactivation of HHV-6 in vivo as well and that reactivation may lead to fetal infection.
Chromosomal integration of HHV-6 may be the mechanism responsible for congenital infection with HHV-6 in 2 of our 5 cases of congenital infection. Chromosomal integration is suggested by the repeated detection of HHV-6 DNA in all samples, from all sites, with high viral loads [9] . In addition to chromosomal integration as a mechanism of transmission, our data support active infection with HHV-6 as a separate means of transmission of HHV-6 from mother to fetus. The long-term consequences of congenital infection with HHV-6 are yet to be delineated.
In summary, we found that the rate of detection of HHV-6 DNA in cervical swabs from pregnant women is low (similar to the rate of detection of HHV-7), yet there is a significant association between finding HHV-6 DNA in cervical secretions and PBMC samples that has not been previously recognized. Additionally, active replication of HHV-6 in the placenta was identified and found to be associated with congenital infection, suggesting that HHV-6 infection may be passed from mother to fetus by more than one mechanism.
